Please login to the form below
non-steroidal therapy
This page shows the latest non-steroidal therapy news and features for those working in and with pharma, biotech and healthcare.
Roche out-licenses lebrikizumab rights to Dermira
Other competition is also in the offing including GlaxoSmithKline's asthma therapy Nucala (mepolizumab) and non-steroidal anti-inflammatory tapinarof, which are both in mid-stage testing for atopic dermatitis, and
Latest news
-
FDA green light for Pfizer's eczema drug
Pfizer's blockbuster-in-waiting Eucrisa has been approved by the FDA for eczema, becoming the first non-steroidal therapy for the skin condition in more than 15 years.
-
Pfizer adds eczema drug with $5.2bn Anacor acquisition
Expands innovative products business with non-steroidal therapy Crisaborole. Pfizer has snapped up Californian biopharma company Anacor in a $5.2bn deal that gives it a late-stage eczema candidate. ... and if approved would be the first new non-steroidal
-
Novartis wins childhood arthritis indication for Ilaris in EU
Ilaris gains a new indication as a monthly subcutaneous injection in patients aged two years and older who have not responded to therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and ... The approval] represents another significant milestone in
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Inovio plans late-stage COVID-19 vaccine study in second quarter 2021
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
- AbbVie buys exclusive right to acquire Mitokinin’s Parkinson’s asset
- Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition
- GSK, Vir halt enrolment of phase 3 COVID-19 antibody study
- Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s
- CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Gene Editing and Precision Medicine: The Future of Healthcare?
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- #DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
- Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
Quick links
Infographics
